Abstract | BACKGROUND: MATERIALS AND METHODS: Three human NSCLC cell line xenograft models were used to investigate antitumor effect of bevacizumab and tumor microvessel density (MVD) was analyzed. RESULTS: CONCLUSION: Continuous suppression of angiogenesis by bevacizumab may contribute to the superior efficacy of maintenance treatment containing bevacizumab.
|
Authors | Nobuyuki Ishikura, Mieko Yanagisawa, Mariko Noguchi-Sasaki, Toshiki Iwai, Keigo Yorozu, Mitsue Kurasawa, Masamichi Sugimoto, Kaname Yamamoto |
Journal | Anticancer research
(Anticancer Res)
Vol. 37
Issue 2
Pg. 623-629
(02 2017)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 28179309
(Publication Type: Journal Article)
|
Copyright | Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. |
Chemical References |
|
Topics |
- A549 Cells
- Animals
- Antineoplastic Combined Chemotherapy Protocols
(pharmacology)
- Bevacizumab
(administration & dosage)
- Carcinoma, Non-Small-Cell Lung
(blood supply, drug therapy, pathology)
- Cell Line, Tumor
- Humans
- Induction Chemotherapy
- Lung Neoplasms
(blood supply, drug therapy, pathology)
- Maintenance Chemotherapy
- Male
- Mice, Inbred BALB C
- Mice, Nude
- Neovascularization, Pathologic
(pathology, prevention & control)
- Pemetrexed
(administration & dosage)
- Tumor Burden
(drug effects)
- Xenograft Model Antitumor Assays
|